Alain Bendavid, PhD

Alain Bendavid, PhD is a prominent figure in the life sciences intellectual property field, currently serving as the Director of Intellectual Property at Medicenna Therapeutics Corp.1 He is widely recognized for his significant contributions to the development of CAR T cell therapy, particularly in the area of costimulatory and advanced-generation approaches.23

Professional Background

Dr. Bendavid's expertise lies in several key areas:

Intellectual Property Strategy:: He is highly experienced in developing and managing US and international patent portfolios, with a focus on substantive prosecution and analytics across major jurisdictions.1

CAR T Cell Therapy:: Alain Bendavid is credited as the originator of costimulatory and advanced-generation CAR T cell therapy.23 This groundbreaking work has positioned him as a pioneer in the field of cancer immunotherapy.

Solid Tumor Treatment:: His research interests extend to innovative approaches for treating solid tumors, including the use of functionalized nitinol thin films in combination with CAR-T cells.4

Research and Innovation

Dr. Bendavid's work encompasses cutting-edge developments in cancer treatment:

• He has been involved in research on personalized cell therapy combinations for chronic lymphocytic leukemia (CLL) patients, achieving complete remission in some cases.5
• His innovative approach includes exploring the use of nitinol thin films functionalized with CAR-T cells for solid tumor treatment, demonstrating his commitment to advancing cancer therapies.4

Professional Network

Alain Bendavid maintains an active presence in the scientific community:

• He is based in the Toronto, Canada area.6
• His LinkedIn profile (username: abendavidphd) serves as a platform for sharing insights and connecting with other professionals in the field.12
• He also engages with the scientific community on Twitter under the handle @ABendavidPhD.3

Dr. Bendavid's work at the intersection of intellectual property and advanced cancer therapies positions him as a key figure in the ongoing development of innovative treatments for challenging cancers.